Kytopen

Kytopen is a biotechnology company based in Cambridge, Massachusetts, with a research and development site in Denver, Colorado. Founded in 2017 by Paulo A. Garcia and Cullen Buie, Kytopen focuses on enhancing access to next-generation cell therapies through scalable genome engineering. The company offers a non-viral gene delivery platform known as Flowfect®, which utilizes continuous fluid flow and electric fields to deliver genetic materials like mRNA, DNA, and CRISPR Cas9 RNP to billions of cells quickly. This technology supports high-throughput, automated, and scalable cell engineering. In 2023, Kytopen introduced the Flowfect Discover™ 96-well platform, designed for optimizing genome engineering by allowing fine-tuning of delivery parameters for multiple samples in a single experiment. Kytopen's technologies are applied in immuno-oncology and genetic disorders, with a focus on engineering human cells for therapeutic use. The company is also developing engineered natural killer (NK) cell therapies and has partnered with BioCentriq to enhance gene-editing technology in cell therapy manufacturing. Kytopen's mission is to improve patient access to innovative cell therapies by addressing manufacturing challenges.